The VITAH Trial Vitamin D supplementation and cardiac autonomic tone in hemodialysis: A blinded, randomized controlled trial

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Mann, Michelle C ^a   Exner, Derek V ^a,b   Hemmelgarn, Brenda R ^a,c   Hanley, David A ^a,d   Turin, Tanvir C ^a   Macrae, Jennifer M ^a   Ahmed, Sofia B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Osteoporosis and Metabolic Bone Disease Centre   (Canada)

Author keywords

Alfacalcidiol; Autonomic nervous system; Cardiovascular risk; Chronic kidney disease; Clinical trial; Ergocalciferol; Vitamin D

Indexed keywords

ALFACALCIDOL; ERGOCALCIFEROL; PLACEBO; VITAMIN D;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CARDIAC AUTONOMIC TONE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART FUNCTION; HEART RATE VARIABILITY; HEMODIALYSIS; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART RATE; KIDNEY FAILURE, CHRONIC; PHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY; VITAMIN D DEFICIENCY;

CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84906538277     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-129     Document Type: Article

References (48)

1. 2013 CORR Report, Treatment of End-Stage Organ Failure in Canada, 2002 to 2011 Ottawa Ontario Canada: Canadian Institute for Health Information 2013
2. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Foley RN, Semin Dial 2003 16 2 111 117 12641874
3. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators, N Engl J Med 2005 353 3 238 248 10.1056/NEJMoa043545 16034009
4. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samulsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Johnsson E, Zannad F, AURORA Study Group, N Engl J Med 2009 360 14 1395 1407 10.1056/NEJMoa0810177 19332456
5. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, et al. Lancet 2011 377 9784 2181 2192 10.1016/S0140-6736(11)60739-3 21663949
6. Digoxin associates with mortality in ESRD. Chan KE, Lazarus JM, Hakim RM, J Am Soc Nephrol 2010 21 9 1550 1559 10.1681/ASN.2009101047 20576808
7. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Malik M, Circulation 1996 93 5 1043 1065 10.1161/01.CIR.93.5.1043 8598068
8. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Oikawa K, Ishihara R, Maeda T, Yamaguchi K, Koike A, Kawaguchi H, Tabata Y, Murotani N, Itoh H, Int J Cardiol 2009 131 3 370 377 10.1016/j.ijcard.2007.10.033 18199499
9. Autonomic dysregulation in patients awaiting kidney transplantation. Hathaway DK, Cashion AK, Milstead EJ, Winsett RP, Cowan PA, Wicks MN, Gaber AO, Am J Kidney Dis 1998 32 2 221 229 10.1053/ajkd.1998.v32.pm9708605 9708605
10. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Ranpuria R, Hall M, Chan CT, Unruh M, Nephrol Dial Transplant 2008 23 2 444 449 18003665
11. Measurement of heart rate variability: a clinical tool or a research toy? Huikuri HV, Makikallio T, Airaksinen KE, Mitrani R, Castellanos A, Myerburg RJ, J Am Coll Cardiol 1999 34 7 1878 1883 10.1016/S0735-1097(99)00468-4 10588197
12. Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Hayano J, Takahashi H, Toriyama T, Mukai S, Okada A, Sakata S, Yamada A, Ohte N, Kawahara H, Nephrol Dial Transplant 1999 14 6 1480 1488 10.1093/ndt/14.6.1480 10383012
13. Heart rate variability in patients with end-stage renal disease: an emerging predictive tool for sudden cardiac death? Chan CT, Nephrol Dial Transplant 2008 23 10 3061 3062 10.1093/ndt/gfn280 18503010
14. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Chan CT, Hanly P, Gabor J, Picton P, Pierratos A, Floras JS, Kidney Int 2004 65 2 661 665 10.1111/j.1523-1755.2004.00384.x 14717939
15. Determinants of cardiac autonomic dysfunction in ESRD. Chan CT, Levin NW, Chertow GM, Larive B, Schulman G, Kotanko P, Clin J Am Soc Nephrol 2010 5 10 1821 1827 10.2215/CJN.03080410 20616163
16. Heart rate variability-a therapeutic target? Routledge HC, Chowdhary S, Townend JN, J Clin Pharm Ther 2002 27 2 85 92 10.1046/j.1365-2710.2002.00404.x 11975691
17. Heart rate variability measurements and the prediction of ventricular arrhythmias. Reed MJ, Robertson CE, Addison PS, QJM 2005 98 2 87 95 10.1093/qjmed/hci018 15671474
18. Heart rate variability: measurement and clinical utility. Kleiger RE, Stein PK, Bigger JT Jr, Ann Noninvasive Electrocardiol 2005 10 1 88 101 10.1111/j.1542-474X.2005.10101.x 15649244
19. Heart rate variability analysis: a tool to assess cardiac autonomic function. Lewis MJ, Comput Inform Nurs 2005 23 6 335 341 10.1097/00024665-200511000-00011 16292049
20. Uremic autonomic neuropathy studied by spectral analysis of heart rate. Vita G, Bellinghieri G, Trusso A, Costantino G, Santoro D, Monteleone F, Messina C, Savica V, Kidney Int 1999 56 1 232 237 10.1046/j.1523-1755.1999.00511.x 10411697
21. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Fukuta H, Hayano J, Ishihara S, Sakata S, Mukai S, Ohte N, Ojika K, Yagi K, Matsumoto H, Sohmiya S, Kimura G, Nephrol Dial Transplant 2003 18 2 318 325 10.1093/ndt/18.2.318 12543887
22. Why "Vitamin D" is not a hormone, and not a synonym for 1,25-dihydroxy-vitamin D, its analogs or deltanoids. Vieth R, J Steroid Biochem Mol Biol 2004 89-90 1-5 571 573
23. Ergocalciferol and cholecalciferol in CKD. Nigwekar SU, Bhan I, Thadhani R, Am J Kidney Dis 2012 60 1 139 156 10.1053/j.ajkd.2011.12.035 22560832
24. Vitamin D therapy in chronic kidney disease and end stage renal disease. Melamed ML, Thadhani RI, Clin J Am Soc Nephrol 2012 7 2 358 365 10.2215/CJN.04040411 22193236
25. Vitamin D deficiency and risk of cardiovascular disease. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS, Circulation 2008 117 4 503 511 10.1161/CIRCULATIONAHA.107.706127 18180395
26. Vitamin D levels and early mortality among incident hemodialysis patients. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R, Kidney Int 2007 72 8 1004 1013 10.1038/sj.ki.5002451 17687259
27. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H, J Clin Endocrinol Metab 2008 93 10 3927 3935 10.1210/jc.2008-0784 18682515
28. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, Wanner C, Boeschoten EW, Brandenburg V, NECOSAD Study Group, Nephrol Dial Transplant 2011 26 3 1024 1032 10.1093/ndt/gfq606 20947538
29. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, März W, Ritz E, Wanner C, Eur Heart J 2010 31 18 2253 2261 10.1093/eurheartj/ehq246 20688781
30. Rapid stimulation of calcium uptake and protein phosphorylation in isolated cardiac muscle by 1,25-dihydroxyvitamin D3. Selles J, Boland R, Mol Cell Endocrinol 1991 77 1-3 67 73 1816004
31. Evidence on the participation of the 3′,5′-cyclic AMP pathway in the non-genomic action of 1,25-dihydroxy-vitamin D3 in cardiac muscle. Selles J, Boland R, Mol Cell Endocrinol 1991 82 2-3 229 235 1665453
32. Modulation of calcium uptake in cultured cardiac muscle cells by 1,25-dihydroxyvitamin D3. Selles J, Bellido T, Boland R, J Mol Cell Cardiol 1994 26 12 1593 1599 10.1006/jmcc.1994.1179 7731054
33. Calcitriol modulation of cardiac contractile performance via protein kinase C. Green JJ, Robinson DA, Wilson GE, Simpson RU, Westfall MV, J Mol Cell Cardiol 2006 41 2 350 359 10.1016/j.yjmcc.2006.05.019 16815434
34. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK, Nephron Clin Pract 2006 102 1 21 29 10.1159/000088295 16166802
35. 25-hydroxyvitamin D status, arterial stiffness, and the renin angiotensin system in healthy humans. Abdi-Ali A, Nichol DDM, Hemmelgarn BR, MacRae JM, Sola DY, Ahmed SB, Clin Exp Hypertens 2013 in press
36. Vitamin D levels are associated with cardiac autonomic activity in healthy humans. Mann MC, Exner DV, Hemmelgarn BR, Turin TC, Sola DY, Ellis L, Ahmed SB, Nutrients 2013 5 6 2114 2127 10.3390/nu5062114 23752493
37. Vitamin D supplementation is associated with improved modulation of cardiac autonomic tone. Mann MC, Exner DV, Hemmelgarn BR, Sola DY, Turin TC, Ahmed SB, Int J Cardiol 2014 172 2 506 8 10.1016/j.ijcard.2014.01.058 24502876
38. KDGIO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, Kidney Int Suppl 2009 76 113 1 S130
39. IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Mayne ST, Ross AC, Shapses SA, Taylor CL, J Clin Endocrinol Metab 2012 97 4 11467 52
40. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Manns BJ, Hodsman A, Zimmerman DL, Mendelssohn DC, Soroka SD, Chan C, Jindal K, Klarenbach S, Am J Kidney Dis 2010 55 5 800 812 10.1053/j.ajkd.2010.02.339 20438984
41. Vitamin D3 Therapy Corrects the Tissue Sensitivity to Angiotensin II Akin to the Action of a Converting Enzyme Inhibitor in Obese Hypertensives: An Interventional Study. Vaidya A, Sun B, Larson C, Forman JP, Williams JS, J Clin Endocrinol Metab 2012
42. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P, Neurology 2010 74 23 1852 1859 10.1212/WNL.0b013e3181e1cec2 20427749
43. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF, Cochrane Database Syst Rev 2009 4 CD005633
44. The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Li Y, Muruve DA, Collins RG, Lee SS, Kubes P, Eur J Immunol 2002 32 12 3443 3452 10.1002/1521-4141(200212)32:12<3443::AID-IMMU3443>3.0.CO;2-F 12442326
45. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. Thadhani R, Appelabum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD, JAMA 2012 307 7 674 84 10.1001/jama.2012.120 22337679
46. Vitamin D deficiency. Holick MF, N Engl J Med 2007 357 266 81 10.1056/NEJMra070553 17634462
47. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic nephropathy. Kontonopoulous AG, Athyros VG, Didangelos TP, Papagerogiou AA, Avramidis MJ, Mayroudi MC, Karamitsos DT, Diabetes Care 1997 20 3 255 61
48. Effect of paricalcitol on left vantricular mass and function in CKD-the OPERA trial. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM, J Am Soc Nephrol 2014 25 1 175 86 10.1681/ASN.2013010103 24052631